James A Watson

University of Oxford

United Kingdom

Research Interests

Explore related searches

Professors in United Kingdom

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (30)

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Collaborators (9)

Marcus Vinicius Guimarães de Lacerda

Adjunct Professor

University of Texas Medical Branch

UNITED STATES

View details

James A. Seddon

UNITED KINGDOM

View details

Richard Price

University of Oxford

UNITED KINGDOM

View details

Naomi Waithira

Head of Data Management

University of Oxford

UNITED KINGDOM

View details

Roberto Amato

GlaxoSmithKline (United States)

UNITED KINGDOM

View details

Thomas Peto

University of Oxford

UNITED KINGDOM

View details

Nicholas White

University of Oxford

UNITED KINGDOM

View details

Julie Simpson

University of Melbourne

AUSTRALIA

View details

Arjun Chandna

NIHR Academic Clinical Lecturer

London School of Hygiene & Tropical Medicine

UNITED KINGDOM

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

James A Watson

Research Interests

Explore related searches

Contact this professor

Articles (30)

Within-host modeling of primaquine-induced hemolysis in hemizygote glucose-6-phosphate dehydrogenase deficient healthy volunteers

Tuberculosis preventive therapy: scientific and ethical considerations for trials of ultra-short regimens.

Antiviral efficacy of fluoxetine in early symptomatic COVID-19: an open-label, randomised, controlled, adaptive platform trial (PLATCOV).

Lineage-informative microhaplotypes for recurrence classification and spatio-temporal surveillance of Plasmodium vivax malaria parasites

Response to comment on 'The clinical pharmacology of tafenoquine in the radical cure of Plasmodium vivax malaria: An individual patient data meta-analysis'

The relationship between viral clearance rates and disease progression in early symptomatic COVID-19: a systematic review and meta-regression analysis.

Comparison of WHO versus national COVID-19 therapeutic guidelines across the world: not exactly a perfect match.

Temporal changes in SARS-CoV-2 clearance kinetics and the optimal design of antiviral pharmacodynamic studies: an individual patient data meta-analysis of a randomised, controlled, adaptive platform study (PLATCOV).

Spatial Analysis of Drug-Susceptible and Multidrug-Resistant Cases of Tuberculosis, Ho Chi Minh City, Vietnam, 2020-2023.

Where will rectal artesunate suppositories save lives?

Primaquine in glucose-6-phosphate dehydrogenase deficiency: an adaptive pharmacometric assessment of ascending dose regimens in healthy volunteers.

Clinical antiviral efficacy of favipiravir in early COVID-19 (PLATCOV): an open-label, randomised, controlled, adaptive platform trial.

Rectal artesunate: lives not saved

Evaluation of hydroxychloroquine or chloroquine for the prevention of COVID-19 (COPCOV): A double-blind, randomised, placebo-controlled trial.

Methaemoglobin as a surrogate marker of primaquine antihypnozoite activity in Plasmodium vivax malaria: A systematic review and individual patient data meta-analysis

Modeling the within-host dynamics of Plasmodium vivax hypnozoite activation: An analysis of the SPf66 vaccine trial

Advancing the chemotherapy of tuberculous meningitis: a consensus view.

Transmission-blocking activities of artesunate, chloroquine, and methylene blue on <i>Plasmodium vivax</i> gametocytes.

WHO should accelerate, not stall, rectal artesunate deployment for pre-referral treatment of severe malaria

Clinical antiviral efficacy of remdesivir in COVID-19: an open label, randomized, controlled adaptive platform trial (PLATCOV).

The CARAMAL study could not assess the effectiveness of rectal artesunate in treating suspected severe malaria.

Which trial do we need? A global, adaptive, platform trial to reduce death and disability from tuberculous meningitis.

A global core outcome measurement set for snakebite clinical trials.

Pharmacometrics of high-dose ivermectin in early COVID-19 from an open label, randomized, controlled adaptive platform trial (PLATCOV).

Rectal artesunate suppositories for the pre-referral treatment of suspected severe malaria.

Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial.

Population heterogeneity in Plasmodium vivax relapse risk.

The clinical pharmacology of tafenoquine in the radical cure of <i>Plasmodium vivax</i> malaria: An individual patient data meta-analysis.

The prognostic and diagnostic value of intraleukocytic malaria pigment in patients with severe falciparum malaria.

Substantial misdiagnosis of severe malaria in African children.

Collaborators (9)

Marcus Vinicius Guimarães de Lacerda

James A. Seddon

Richard Price

Naomi Waithira

Roberto Amato

Thomas Peto

Nicholas White

Julie Simpson

Arjun Chandna

Make your next move.